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Unconventional functions of mitotic 
kinases in kidney tumorigenesis
Pauline Hascoet , Franck Chesnel , Cathy Le Goff , Xavier Le Goff and  
Yannick Arlot-Bonnemains*
UMR 6290 (IGDR), CNRS, University Rennes-1, Rennes, France
Human tumors exhibit a variety of genetic alterations, including point mutations, translo-
cations, gene amplifications and deletions, as well as aneuploid chromosome numbers. 
For carcinomas, aneuploidy is associated with poor patient outcome for a large variety of 
tumor types, including breast, colon, and renal cell carcinoma. The Renal cell carcinoma 
(RCC) is a heterogeneous carcinoma consisting of different histologic types. The clear 
renal cell carcinoma (ccRCC) is the most common subtype and represents 85% of the 
RCC. Central to the biology of the ccRCC is the loss of function of the Von Hippel–Lindau 
gene, but is also associated with genetic instability that could be caused by abrogation 
of the cell cycle mitotic spindle checkpoint and may involve the Aurora kinases, which 
regulate centrosome maturation. Aneuploidy can also result from the loss of cell–cell 
adhesion and apical–basal cell polarity that also may be regulated by the mitotic kinases 
(polo-like kinase 1, casein kinase 2, doublecortin-like kinase 1, and Aurora kinases). In 
this review, we describe the “non-mitotic” unconventional functions of these kinases in 
renal tumorigenesis.
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iNTRODUCTiON
Renal cell carcinoma (RCC) represents approximately 3.8% of adult malignancies and 90–95% of 
kidney neoplasms. The most common histological RCC subtype is the clear cell carcinoma (ccRCC), 
which accounts for 85% of cases. At least 80% of ccRCCs have deletions or translocations involving 
the short-arm of chromosome 3, which contains the von Hippel–Lindau (VHL) gene at 3p25. Clear 
cell carcinoma shows highly consistent chromosomal aberrations involving loss of the short-arm 
of chromosome 3, a partial or complete trisomy 5q, and abnormalities of 6q, 8p, 9p, 10q, 11q, 12q, 
and 14q. The second most common cytogenetic abnormality associated with ccRCC is a gain of 
chromosome 5q6; however, very little is known about its effects. Mitotic errors and misregulation 
of cell-cycle process are considered to be an important characteristic of kidney cancer. Successful 
cancer therapies depend mainly on the recognition of physiologic targets that are primarily involved 
in the regulatory mechanism of cell-cycle progression (1). The members of serine/threonine kinases, 
such as cyclin-dependent kinases, polo-like kinases, and aurora kinases, are the well studied families 
that coordinate the mitosis sequence (2). Many studies are generally focused on the role of mitotic 
functions of these kinases and efforts have been put up to use targets for generation of new anti-
cancer drugs (3). However other non-mitotic functions of these kinases have been identified as 
diverse as control of the resorption of the cilia, the cell differentiation, and the cell polarity control 
in interphase cells.
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Kidney Cancer and (loss of) Cell Polarity
Carcinomas are frequently characterized by loss of cell 
differentiation and excess of cell proliferation. They are also 
characterized by a loss of cell polarity, which includes polarity 
complexes and adhesion complexes proteins dysfunction (4–6). 
Loss of cell polarity induces cancer development by deregulating 
different signaling pathways (7). Ultimate loss of the epithelial 
phenotype may contribute to epithelial-to-mesenchymal 
transition (EMT) and metastasis. Cell polarity is defined as 
asymmetry in functional organization of the cell. It is required 
for the formation and maintenance of functional epithelia. 
Epithelial cells are highly polarized (i.e., asymmetric distribution 
of lipids, proteins, RNA, organelles) and are tightly connected 
by specialized intercellular junctions. In epithelia, maintenance 
of apico-basal (AB) polarity is crucial for preserving epithelial 
integrity and depends on cell polarity complexes and cell 
junctions. Cell polarity is mostly driven by complexes composed 
of adherens junctional complexes (including cadherin and 
catenin) and tight junctional complexes that contain zonula 
occludens (ZO) proteins, occludin, claudin, and junctional 
adhesion molecules (JAM). These cell polarity complexes have 
antagonistic roles in regulating the specific distribution of key 
molecules. The Scribble complex (Scrib, Dlg, and Lgl2) is present 
in the baso-lateral region of the cell and has antagonistic roles 
with the apical complexes, Par (Par3, Par6, Cdc42, atypical 
protein kinase C) and Crumbs (Crb3, Pals1, and PatJ). Other 
conserved Par proteins such as Lkb1 (Par4) and the Par1 kinase 
regulate cell polarity (8).
In the kidney, the epithelium is a simple tube-based 
structure with the apical membrane facing the lumen whereas 
the basolateral membrane interacts with the matrix. In 
kidney tubes, as well as for podocytes, the establishment and 
maintenance of the epithelium require the presence of the 
Par, Crumbs and Scribble complexes (9). AB polarization of 
the renal epithelium is crucial for the appropriate function of 
the normal kidney in waste products and extra water removal 
and electrolyte balance. Disruption of cell polarity in kidney 
is involved in renal pathologies such as acute renal failure, 
which affects tight junction function (10) and polycystic 
kidney disease (PKD) in which polarity factors are frequently 
mislocalized (11). Polarity complexes expression and 
functions are frequently deregulated in cancer. Implication of 
polarity complex proteins as oncogene or tumor suppressor 
in tumorigenesis depends on the kind of alteration of their 
expression. It is also dependent on the origin of the epithelium 
(12). For instance, Par3 expression is lost in glioblastoma, 
esophageal squamous carcinoma, breast, lung, head, and 
neck cancers (13–16) but is overexpressed in some RCC (17) 
or in some severe hepatocellular carcinoma (18). Thus both 
up- and down-regulation of critical cell polarity proteins may 
be associated with tumorigenesis. Consistent with this notion, 
expression and functional studies in different skin tumors 
showed either oncogenic or tumor-suppressive functions of 
Par3 depending on the cellular context (19).
It has been widely admitted that ccRCC originates from 
proximal epithelial tubular cells. This is based on specific cellular 
marker expression (20, 21) or genetic expression pattern (22). 
However, epithelial cells of other nephron segments may also 
promote some cases of ccRCC. Interestingly, based on studies in 
VHL patients, ccRCC may also arise from VHL-null epithelial 
cells, which show markers of dedifferentiation (23). In colon 
adenocarcinoma, it has been reported that both expression levels 
and subcellular localization of the Scribble polarity complex 
component Dlg could be deregulated. However, in ccRCC, Dlg 
expression level is unaltered compared to normal kidney epithelial 
cells, but the protein is mislocalized in a granular distribution in 
clear cells. It was proposed that altered localization of Dlg may 
contribute to cell transformation and promotes high migration 
ability (24).
In ccRCC, the polarity protein Par3 overexpression is cor-
related with a poor prognosis (17). The localization of Par3 at 
both the plasma membrane and in the cytoplasm was associated 
with worse clinical factors in a cohort of 101 ccRCC patients (25). 
Furthermore, Dugay et al. showed that Par3 up-regulation was 
associated with cytoskeleton defects and increased cell migration 
capacity. This was restored by Par3 down-regulation whereas other 
Par complex component expression levels remained unchanged 
(17). Crumbs3 (Crb3) is involved in establishment of AB polarity 
and formation of tight junctions. Knock-out mice showed strong 
defects in epithelial AB polarity and thus in establishment and 
maintenance of epithelial cells. In contrast to Par3, loss of Crb3 
expression induces tumorigenesis in kidney cells. This effect was 
associated with several characteristics of cell polarity disruption. 
This phenotype was reversed upon restoration of Crb3 expression 
(26, 27). Accordingly, loss of Crb3 is associated with a shorter 
overall survival in ccRCC (28). Altogether, polarity factors mis-
localization and/or their deregulated expression are associated 
with tumor progression. This may be due to altered epithelia 
organization involving cell–cell contact disruption, a higher abil-
ity to transform phenotype (EMT) and for cell migration, and/or 
increased cell proliferation signaling.
Kidney Cancer and eMT
The EMT is known for more than a decade to participate in tumor 
progression and metastasis formation in many carcinomas. This 
process by which epithelial cells acquire a mesenchymal pheno-
type starts with loss of cell–cell adhesion and polarity and leads 
to increased cell motility and invasion. At the molecular level, 
EMT is characterized by the alteration of some gene expression 
profiles resulting in down-regulation of epithelial markers (such 
as E-cadherin, ZO-1, and cytokeratins), and up-regulation of 
mesenchymal markers, such as vimentin (29).
The implication of EMT in clear cell renal cell carcinoma 
(ccRCC) progression and invasiveness has been established 
within the last 5  years, especially when investigators were 
searching for new biomarkers associated with clinical outcome. 
While comparing mRNA levels of 46 EMT-related genes between 
RCC and healthy kidney samples, Chen and colleagues showed 
that low vimentin, CXCR4, fibronectin, and TWIST1 transcript 
levels are correlated with a better outcome whereas overexpressed 
vimentin and CXCR4 constitute independent markers for 
poor prognosis in RCC patients (30). Likewise, using an 
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immunohistochemical approach on a cohort of 122 RCC patients, 
protein expression levels of vimentin, TWIST, E-cadherin, and 
clusterin were identified as predictors of disease recurrence (31). 
Overexpression of zinc-finger transcription factors SNAI1/Snail 
or ZEB2/SIP1, well-known EMT inducers acting as repressors 
of E-cadherin transcription, has also been associated with poor 
prognosis in RCC patients (32, 33). It could result at least in part 
from the loss or a decreased expression of NDRG2 and FOXO3a 
observed in high grade or metastatic RCC tumors, respectively 
(34, 35). Several mechanisms have been proposed to explain how 
EMT is induced and/or sustained during kidney tumorigenesis.
As a consequence of the functional inactivation of VHL very 
often observed in ccRCC, accumulation of Hypoxia-induced 
transcription factors HIF1 and/or 2α leads to the transcriptional 
activation of many HIF target genes. Among them, erythropoi-
etin (EPO) may stimulate EMT in RCC via the PI3K/Akt/mTOR 
pathway (36) in agreement with the observations that the mTOR 
inhibitor Everolimus was able to slow down RCC tumor growth 
and to reverse EMT phenotype in a mouse xenograft model (37). 
At least two proinflammatory cytokines, tumor necrosis factor 
alpha (TNFα) and interleukin 15 (IL-15), have been reported to 
play a role in EMT induction in RCC. Serum levels of TNFα are 
significantly increased in RCC patients as well as secretion by 
tumor cells and it was demonstrated that TNFα promotes EMT 
in RCC by decreasing E-cadherin expression and increasing 
vimentin expression and MMP9 activity (38, 39). This TNFα 
effect is mediated through the inhibition of GSK3β in a NFκB-
independent manner (39, 40). In contrast, IL-15 production is 
not altered in RCC but the IL-15 signaling pathway is profoundly 
modified because of the expression of a particular transmembrane 
IL-15 form and the defective expression of CD132 (γc chain of 
the IL-2 receptor family) and JAK3 (41), which both favor EMT 
through down-regulation of E-cadherin expression (42).
Kidney Cancer and Angiogenesis
To proliferate, cancer cells require a continuous supply of nutrients 
and oxygen. This supply is function of the distance between 
tumor vessels and cancer cells, leading to intratumoral hypoxia 
heterogeneity (43). To overcome this phenomenon, angiogenesis 
is up-regulated in most cancers, due to an overproduction of 
angiogenic stimulators and the consequent unbalanced proportion 
of activators (such as VEGF, MMPs, FGF, HGF…) and inhibitors 
(such as thrombospondins, endostatin, angiostatin…) in favor of 
the hyperactive tumor vasculature development (44). Therefore, 
tumor vessels are disorganized, tortuous, and mal-shaped with 
fewer mural pericytes (45). Moreover, proliferating cancer cells 
can also exert a pressure on intratumoral blood and lymphatic 
vessels (46) leading to an impaired blood perfusion. These 
vascular abnormalities lead to a hypoxic, acidic, and hypertensive 
tumor microenvironment. Adaptation to hypoxia at the cellular 
level is mainly regulated by the Hypoxia Inducible Factors (HIFs).
In ccRCC, the HIF system is up-regulated both by micro-
environmental hypoxia and a genetic event, the VHL inactivation, 
that lead to HIF-α stability. Indeed, the VHL gene is deleted, 
mutated or hypermethylated in ~90% of the cases, leading to the 
absence or to the expression of a non-functional pVHL protein (47). 
HIFs, the main targets of pVHL, are transcription factors 
responsible for numerous hypoxia responses by promoting 
expression of genes involved in the cellular adaptation to hypoxia. 
In normoxia, the oxygen-dependent prolyl hydroxylated domain 
containing proteins (PHDs) specifically hydroxylate HIF-α 
in its N-terminal transactivation domain (NTAD) (48, 49), 
allowing its interaction with pVHL, the substrate recognition 
subunit of an E3 ubiquitin ligase complex, and its subsequent 
degradation by the 26S proteasome (50). HIF-α can also be 
hydroxylated in an oxygen-dependent manner on its C-terminal 
transactivation domain (CTAD) by the Factor Inhibiting HIF 
(FIH-1). This hydroxylation prevents the recruitment of the 
transcriptional co-activators CBP and p300. Thus, under low 
oxygen conditions or in absence of a functional pVHL, HIF-α 
is stabilized and can dimerize with the stable HIF-β, and this 
heterodimer transcriptionally activates up to 200 genes involved 
in cell growth, glucose metabolism, angiogenesis, apoptosis, pH 
regulation… One of the most described targets of HIFs is the 
vascular endothelial growth factor (VEGF). It is overexpressed 
at the mRNA and protein levels in ccRCC compared to normal 
kidney tissues (51, 52). Endothelial cells but also RCC cells 
express the VEGF Receptor (VEGFR-2), inducing increased 
tumor angiogenesis. VEGF and its receptor constituted the 
main targets for metastatic RCC treatments such as Sunitinib, 
Sorafenib, Pazopanib, and Bevacizumab (53–55). However, 
most of the ccRCC patients develop resistance to these VEGF 
inhibitors. mTOR inhibitors (Temsirolimus and Everolimus) 
were also used for RCC treatment by acting downstream of the 
VEGF receptor through HIF down-regulation since mTORC1 
drives HIF-1α synthesis (56).
The HIFα family is composed of three different members 
(HIF-1α, HIF-2α, and HIF-3α). HIF-1α is ubiquitously expressed 
whereas HIF-2α expression is more restricted, but both isoforms 
are co-expressed in numerous cell types. HIF-1α and HIF-2α have 
common and also unique targets and are thought to have overlap-
ping functions, but also divergent outcomes in tumorigenesis. In 
fact, HIF-1α and HIF-2α were first considered as essential for 
ccRCC progression but several studies tend toward an oncogenic 
role for HIF-2α in ccRCC and a tumor suppressor function for 
HIF-1α (23, 57, 58). Moreover, most of the VHL−/− ccRCC cell 
lines do not express HIF-1α whereas they all express HIF-2α, 
suggesting a selective pressure to maintain HIF-2α expression.
Kidney Cancer and Ciliogenesis
Kidney epithelial cells have developed primary cilia that extend 
into the tubular lumen. This includes cells in the parietal layer 
of Bowman’s capsule, proximal tubules, the loop of Henle, and 
the collecting duct. Cilia are present on almost all cells lining the 
nephron, with the exception of intercalated cells (59).
In the kidney, the cilium serves as a flow sensor in the kidney 
tubules lumen, with flow-induced ciliary bending causing a 
transient increase in intracellular calcium (60). Polycystins (PC) 
1 and 2, gene products of PKD1 and PKD2, are large multi-pass 
transmembrane proteins of the transporter receptor potential 
channel (TRPC) family of calcium transporters. Mutations of 
PKD1 and PKD2 induce cyst formation in the kidney, and cyst 
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formation in part arises because of derestricted cell proliferation. 
Thus PC1 and PC2 at least indirectly participate in cell-cycle 
control. Signaling downstream of PC1 and PC2 is quite complex. 
In normal cells, these proteins negatively regulate the cAMP and 
Raf–MEK–ERK signaling pathways (61), both of which being 
hyper activated in renal epithelial cysts (62).
The primary cilium of the kidney epithelium mediates sensa-
tion of mechanical signals produced by apical fluid shear stress 
and its transduction into an intracellular Ca2+ signaling response 
(63, 64). In cell culture, deflection of the cilia axoneme initiates a 
transient increase in the level of intracellular Ca2+ resulting from 
Ca2+ entry through a channel, possibly PC1 and PC2, located in 
the cilium. This is supported by the fact that the Ca2+ influx gener-
ated by fluid flow is abolished in cell lines lacking polycystin-1 
(65) and by the loss of fluid flow-mediated calcium signaling in 
the embryo.
Accordingly, defects in assembly or function of primary cilia 
lead to a plethora of developmental disorders and pathological 
conditions known as ciliopathies (66). Cystic kidney disorders 
are one of the leading causes of end-stage renal disease. Several 
proteins implicated in the pathogenesis of PKD localize to cilia. 
In the growth of the renal normal tubule, the mitotic spindle 
of dividing cells aligns along the axis of the nephron. However, 
in cells with mutations within Pkhd1 (encoding fibrocystin) as 
well as Hnf-1 genes, the spindle fails to correctly orient inducing 
abnormal cell division (67).
An important feature of ciliary signaling is the continuous 
interaction with regulatory signaling molecules at the ciliary 
base, i.e., the centrosomal region, which may coordinate the 
crosstalk between separate ciliary signaling pathways to activate 
specific cellular targets and gene arrays for specified cellular or 
tissue responses (67, 68).
The VHL disease is caused by germline mutation in the vhl 
tumor suppressor gene. One of the major clinical manifesta-
tions of the disease includes kidney tumor. Around 80% of the 
VHL patients developed renal cysts. pVHL localized to the cilia. 
Ectopic expression of VHL gene in renal clear cell carcinoma cell 
lines restored cilia formation, implying that pVHL might directly 
support ciliogenesis (69). Inactivation of VHL and GSK-3b was 
required to allow loss of cilia based on cooperative function 
of these proteins in ciliary maintenance. pVHL also regulates 
microtubule orientation during ciliogenesis and interacts with the 
Par3–Par6-atypical PKC complex, which supports ciliogenesis 
(70). Moreover, pVHL associates with kinesin 2, allowing pVHL 
to influence microtubule dynamics in support of cilia (71, 72).
Genetic instability and Kidney Cancer
A large proportion of tumors are aneuploid and this abnormal 
number of chromosomes is thought to contribute to tumorigen-
esis. It is associated with poor prognosis, multidrug resistance, 
and increased capacity to metastasis. Genomic instability may be 
the result of several mitotic defects (73–75).
During mitosis, the formation of a bipolar mitotic spindle is 
essential for proper chromosome segregation. The chromosome 
segregation mediated by the anaphase-promoting complex/
cyclosome (APC/C) is controlled by the spindle assembly 
checkpoint (SAC). This checkpoint arrests cell-cycle progression 
by modulating the activity of the mitotic kinase CDK1 until all 
chromosomes are properly attached to the mitotic spindle (76, 
77). The chromosomal passenger complex (CPC), composed of 
Aurora-B, INCENP, Borealin, and Survivin, plays also a critical 
role at different stages of mitosis and cytokinesis by recruiting 
condensin complex in mitotic entry (78, 79) and by activating 
SAC in metaphase if chromosomes are not properly attached to 
the spindle. Its relocalisation from anaphase chromosomes to 
cell equator promotes mitotic exit and cytokinesis (80). Hence, 
deregulated CDK1 activation, weakened mitotic checkpoint, 
defective chromatid cohesion or condensation, may contribute 
to genomic instability. Indeed several alterations in mitotic genes 
have been reported in human cancer with chromosome instability 
(81). The duplication and maturation of centrosome is a critical step 
for the formation of a bipolar mitotic spindle. Thus, centrosome 
amplification, enrichment for centrosome components [such as 
CDK1, NEK2, Aurora-A, Aurora-B, or Polo-like kinase 1 (Plk1)] 
or merotelic attachment of chromosomes to the mitotic spindle 
may promote abnormal cell division and aneuploidy (77, 82, 83).
A recent study on VHL showed that this protein is a controller 
of mitotic fidelity in  vivo (84). VHL is localized to the mitotic 
spindle. The loss of function of pVHL in cellulo and in  vivo 
provokes spindle misorientation as a result of unstable astral MT 
and chromosome instability due to SAC impairment (85, 86). 
This aneuploidy phenotype in VHL-deficient renal carcinoma cell 
lines is suppressed by ectopic expression of Mad2, a regulator of 
APC/C (85) or inhibition of miR-28-5p, a key regulator of Mad2 
protein translation upregulated in a variety of cancers (84, 87). This 
result suggests that low level of Mad2 is linked to chromosomal 
instability (CIN) in VHL-associated kidney cancers (86).
It has been observed that the VHL loss of function is not 
sufficient to explain tumor formation in kidney. Recently, Albers 
et al. have shown that secondary genetic alterations of p53 can 
cooperate with loss of pVHL to induce tumors in mice (88). 
Detailed cytogenetic analysis of tumor at different stages and 
gene expression analysis are necessary to understand tumor 
development and the molecular basis that contribute to aneuploidy.
Non-Mitotic Roles of Mitotic Kinases in 
Kidney Cancer
Polo-Like Kinase 1
Polo-like kinase 1 is the best characterized member of the Plks 
family (89). This serine/threonine kinase is known to regulate 
multiple stages of mitosis. Its expression is cell-cycle regulated 
since it increases from late S phase to mitosis, and its degradation 
mediated by APC/C starts in late mitosis. In interphase, Plk1 is 
expressed in the cytoplasm and at the centrosomes whereas in 
mitosis, it localizes to the centrosomes in prophase, then becomes 
enriched at kinetochores during prometaphase and metaphase, 
and in late mitosis a fraction of Plk1 is found at the spindle 
midzone (90). Plk1 is not only involved in the assembly of a 
bipolar spindle, centrosomes duplication and maturation, DNA 
replication, and DNA damage checkpoint, but also in the control 
of the G2/M transition. Several studies demonstrate its role not 
only in sister chromatid dissociation but also in mitotic exit and 
cytokinesis [reviewed in Ref. (91, 92)].
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Since Plk1 is a key regulator of the cell division, it evidently 
appeared as an interesting target for anti-mitotic chemotherapeutic 
drugs (93). Small-molecule inhibitors of Plk1 activity have been 
developed. Several phase II trials were performed in solid tumors 
using for instance BI2536, a Plk1 inhibitor, but it exhibited a 
limited anti-tumoral activity, suggesting that more favorable 
pharmacological derivates are required (94). Despite these 
non-conclusive trials, Plk1 remains a promising target since 
it is overexpressed in a number of human tumors: esophageal 
squamous cell carcinoma (95), hepatocellular carcinoma (96), 
bladder carcinoma (97), thyroid carcinoma (98, 99), colorectal 
cancer (100), pancreatic cancer (101), prostate cancer (102), 
melanoma (103), breast cancer (104), and ovarian cancer (105). Its 
overexpression is often correlated with tumor grade, sometimes 
with metastatic disease (103), and proposed as prognosis factor. 
Interestingly, a gene expression profiling performed on ccRCC 
patient primary tumors identified Plk1 as significantly correlated 
with disease malignancy (106). Plk1 is overexpressed at the 
mRNA and protein level in RCC patient tissues (107) and this 
overexpression is correlated with the tumor grade and metastases. 
Moreover, Plk1 knock-down by siRNA strategy or small-molecule 
inhibitor decreased ccRCC cell proliferation in  vitro by G2/M 
blockade (106) and invasion properties (107). To date, no clinical 
trial was performed using Plk1 inhibitors alone or in combination 
with other drugs in RCC patients. Intratumoral injections of Plk1 
inhibitor in ccRCC xenograft nude mice induced a tumor volume 
decrease indicating that a sustained inhibition of Plk1 function 
may inhibit ccRCC tumor growth in  vivo (106). Intriguingly, 
another in vivo study reported that a liposomal anti-Plk1 siRNA 
delivery system failed to inhibit tumor growth in a mouse 
xenograft RCC model (108).
Non-mitotic functions were recently attributed to Plk1, 
including a role in cilia disassembly. Indeed, an overexpression of 
Plk1 dramatically reduces the length and the percentage of primary 
cilia whereas the depletion of Plk1 or the inhibition of its kinase 
activity induces a delay in cilia disassembly (109). Even if Plk1 
is not required for proper ciliogenesis (110), Lee and colleagues 
identified a new primary cilia disassembly pathway mediated by 
Wnt5a, CK1ϵ, Dvl2, and Plk1 (111). Under growth stimulation, 
the non-canonical ligand of the Wnt pathway, Wnt5a, enhances 
the Plk1 bound to Dvl-2, formerly phosphorylated by CK1ϵ. This 
interaction stabilizes HEF1 and the HEF1/AurA complex, leading 
to the HEF1/AurA dependent primary cilia disassembly. Another 
study has demonstrated that Plk1 is recruited to the pericentriolar 
matrix by PCM1, a centriolar satellite protein (109). This interaction 
requires prior phosphorylation of PCM1 by CDK1. Then, Plk1 is 
activated by Aurora-A and promotes primary cilia disassembly. 
Moreover, KIF2A, a member of the kinesin-13 protein family with 
only an ATP-dependent microtubule depolymerization activity, is 
phosphorylated by Plk1 at the level of subdistal appendages of the 
mother centriole (112). This event enhances MT depolymerization 
to disassemble primary cilia. KIF24, another kinesin-13 protein, 
was previously described to suppress inappropriate ciliogenesis 
in proliferating cells by stabilizing CP110 (113). In quiescent 
cells, KIF2A and KIF24 are both ubiquitinated by APC/C, which 
may prevent a premature initiation of cilia disassembly (112). 
Interestingly, this Plk1–KIF2A pathway was found constitutively 
active and described as involved in defective ciliogenesis in a 
ciliopathy named premature chromatid separation (PCS) syndrome 
(114). Of note, Plk1 was also associated to another ciliopathy, the 
nephronophthisis (NPH), a cystic kidney disease. Indeed, Plk1 
colocalizes at the transition zone of the cilia with nephrocystin 1 
(NPHP1), a scaffold protein of the NPH protein complex frequently 
mutated in NPH patients. Plk1 phosphorylates NPHP1, leading to 
cilia disassembly (115). The function of this phosphorylation and its 
link with cilia disassembly remain to be determined, but this study 
highlighted another signaling role for Plk1 in cilia disassembly 
at the transition zone. Further investigations are needed to study 
whether the non-mitotic function of Plk1 in cilia disassembly is 
involved in ccRCC development since this pathology is strikingly 
linked to cystic lesions and thus cilia defects.
Casein Kinase 2
Casein kinase 2 (CK2) is a ubiquitously expressed and much 
conserved serine/threonine protein kinase, which is composed of two 
catalytic α- (or α′-) and two regulatory β-subunits. This constitutively 
active kinase is involved in cell proliferation and survival; it exerts 
pleiotropic effects throughout cell-cycle progression and notably 
during mitosis, when CK2α is transiently hyperphosphorylated 
(116). During the G2-M transition, it first plays a role in chromatin 
condensation by phosphorylating DNA topoisomerase 2α (117). 
It also participates in the activation of M-phase promoting 
factor, CDK1-cyclin B, both by phosphorylating/activating the 
phosphatase CDC25B and by facilitating PLK1-mediated Wee1 
inhibition (118, 119). CK2 is then located on the mitotic apparatus 
in a Pin-1-dependent manner where it shares with Plk1 the 
microtubule plus-end-tracking protein CLIP170 as a substrate, 
the phosphorylation of which regulates the timely microtubule-
kinetochore attachment and contributes to proper chromosome 
alignment at metaphase (120). Together with the Aurora-B mitotic 
kinase, CK2 is later involved in spindle elongation and chromosome 
segregation during anaphase in yeast and interestingly, loss of CK2 
activity has been shown to activate SAC (121).
Casein kinase 2 has been shown to be overexpressed, and its 
activity increased, in ccRCC compared to healthy kidney (122), 
as reported in many other cancer types. Such deregulation of 
CK2 activity during mitosis may be sufficient to cause mitotic 
chromosome instability and the ensuing aneuploidy that have 
been established to promote tumorigenesis. There is however 
evidence from several reports regarding solid tumors to suggest 
that overexpression of CK2 could also influence kidney tumor 
development through non-mitotic mechanisms. First, CK2 
could exacerbate angiogenesis in hypoxic renal tumors since the 
potent and selective small molecule CK2 inhibitor CX-4945 (also 
called silmitasertib) has been shown to exert anti-tumor activity 
through inhibition of angiogenesis in breast cancer (123). This 
proangiogenic effect of CK2 has been recently discussed [see for 
review in Ref. (124)]; it is likely the result of several possible actions 
of the kinase in the signaling cascade leading to hypoxia-mediated 
transcription of HIF target genes (see Figure 1 for details).
Proangiogenic effect of overexpressed CK2 could additionally 
be mediated by local overproduction, by tumoral and peripheral 
blood mononuclear cells, of prostaglandin E2 (PGE2), the 
most predominant and biologically active eicosanoid produced 
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by cyclooxygenase 2 (COX-2); this enzyme is indeed often 
upregulated in ccRCC, likely through a CK2-induced Wnt/β-
catenin pathway and its expression is correlated with prognosis 
[see for review in Ref. (130)].
Besides, overexpression of COX2 is also associated with 
tumor cell migration and invasion as well as the PGE2 receptor 
EP4, the expression of which is strongly correlated with ccRCC 
tumor stage and aggressiveness and the presence of metastases 
(130) but there is to date no such available data connecting CK2 
expression levels and tumor progression. A few recent studies 
on other solid tumors (lung and colon) nevertheless suggest that 
CK2 could also be involved in the EMT: CK2α is overexpressed 
in colorectal cancer compared to adenoma or healthy colorectal 
tissue and its silencing by RNA interference, while slowing 
down tumor cell proliferation also inhibited cell motility and 
invasion. At the molecular level, CK2α knock-down was able 
to reverse the EMT process by decreasing vimentin expression 
and upregulating E-cadherin (131). Similar observations were 
reported in A549 lung adenocarcinoma cells in which CK2 
inhibition with CX-4945 strongly decreased cell migration and 
invasion at least through the attenuation of PI3K/AKT and ERK 
signaling pathways and blocked TGF-β-induced EMT (132, 133). 
Further investigation is worth pursuing in ccRCC to reveal such 
implication of overexpressed CK2 in EMT process and in the 
regulation of tumoral cell migration and invasion.
Doublecortin-Like Kinase 1
Doublecortin-Like Kinase 1 (DCLK1) was first isolated in 
Caenorhabditis elegans as the product of the zyg-8 gene. Zyg-8 
FiGURe 1 | Overexpressed CK2 induces HiFα accumulation through 
vHL-dependent or independent mechanisms. CK2 can down-regulate 
VHL expression at the transcriptional level (i) by phosphorylating HDACs (125) 
as well as at post-translational level and (ii) by destabilizing phosphorylation in 
the NH2-terminal acidic domain of VHL (126). In the latter case, CK2-induced 
destabilization of VHL also results in p53 inactivation, which can no longer 
inhibit HIFα transcription (iii); (126, 127). Finally, (iv) cdc37 phosphorylation by 
CK2 allows HSP90/cdc37 dimer formation and the subsequent interaction of 
this complex with HIF-1α, which is essential for its cellular stability (128, 129).
loss-of-function alleles were isolated in a visual screen for 
mutants deficient in spindle positioning in the C. elegans one-cell 
stage embryo. The phenotype was due to shortening of astral MT 
during anaphase leading to a defect in spindle-cortex interac-
tion. ZYG-8 is a microtubule-associated protein (MAP), which 
promotes MT stabilization. ZYG-8 encodes a protein kinase 
that harbors a catalytic kinase domain and a domain similar 
to human Doublecortin (DCX), a MAP, which stimulates MT 
polymerization. Both domains are required for its function in C. 
elegans where ZYG-8 localizes to MT. ZYG-8 kinase also binds to 
MT in vitro and in vivo through its DCX domain in mammalian 
cells. ZYG-8 function is required to maintain spindle architecture 
during anaphase and influences spindle positioning and thus 
the proper progression of mitosis (134). Later, it was shown 
that DCLK is a MT-associated kinase, which regulates spindle 
formation in neuronal cells. DCLK overexpression induced large 
monopolar spindles and a prometaphase arrest in mitotic neu-
ronal cells. On the other hand, DCLK silencing perturbed mitotic 
spindle organization with shorter and thinner MT also promot-
ing prometaphase arrest (135). Thus, in metazoans, DCLK1 has a 
conserved mitotic function in regulating spindle formation.
Doublecortin-Like Kinase 1 was identified as a marker of 
tumor stem cells (TSC) for instance in pancreatic and colorectal 
cancers (136) and is upregulated in many other solid tumors. 
It has been recently suggested that DCLK1 may constitute a 
potential relevant diagnostic and prognostic marker of circulating 
cancer cells [e.g., pancreatic adenocarcinoma (137)]. RCC 
cells share many characteristics with TSC, including an EMT 
phenotype. Interestingly, DCLK1 is epigenetically dysregulated 
and overexpressed in more than 90% of RCC tumors. Increased 
expression of DCLK1 correlates with stages II and III tumors. 
Expression of DCLK1 was correlated with the EMT phenotype in 
RCC. Consistently, silencing of DCLK1 in renal Caki-2 cell line 
promoted EMT-specific transcription factors down-regulation 
(SNAI1/SNAI2, TWIST1, and ZEB1) and reduced migration 
and invasion capacities. A decreased adhesive phenotype was 
also observed and correlated with a decrease in the expression of 
the focal adhesion regulator PTK2 (FAK). DCLK1 may regulate 
migration and invasion through the maintenance of focal 
adhesion (138). Whether MT and F-actin binding of DCLK1 
is involved in its adhesion function remains to be investigated. 
Interestingly, it has been recently suggested that phosphorylation 
of FAK by the sphingosine kinase-1 may promote renal cell 
invasion (139). Thus DCLK1 may contribute to the metastatic 
process and targeting this kinase should be considered as part of 
an anti-cancer therapy (140).
Aurora-A Kinase
Aurora-A is a centrosomally localized cell-cycle regulatory ser-
ine/threonine kinase that activates the cyclin B1-Cdk1 mitotic 
kinase and coordinates formation of a bipolar spindle and nuclear 
envelope breakdown in M phase. The serine/threonine kinase 
Aurora-A localizes on duplicated centrosomes from the end of 
S phase to the beginning of the following G1 and is essential for 
mitotic entry, centrosome duplication, spindle formation, chro-
mosome segregation, and cytokinesis (141). Aurora-A is activated 
by phosphorylation from the end of S phase until the next G1 when 
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the kinase is ubiquitinated and degraded by the proteasome in a 
Cdh1-dependent manner (142, 143). The major roles of Aurora-A 
kinase have been widely described in the centrosome separation 
and spindle formation. Aurora-A is activated mainly by Ajuba 
(144); TPX2, Bora, as well as protein phosphatase inhibitor-2 
(145, 146) and the focal scaffolding proteins HEF1 and NEDD9 
(72). Phosphorylation of Aurora-A on T288 residue within the 
activation loop of the catalytic domain results in the activation of 
the protein. Aurora-A has multiple other phosphorylation sites 
modulating its mitotic and non-mitotic activities (S51, S53/S54, 
S66/S67, S89, S98, and S342 residues) (147). The relevance of the 
different phosphorylation sites is not actually well known.
The human Aurora-A gene resides at chromosome 20q13.2, 
a region that is commonly amplified in primary breast tumors, 
colorectal cancers, and other cancer cell lines, including breast, 
ovarian, colon, prostate, neuroblastoma, and cervical cell lines 
(148). Aurora-A abnormalities have been reported in a variety of 
malignant tumors correlated with an Aurora-A gene amplifica-
tion or upregulation of Aurora-A expression in tumor tissues 
compared with normal tissues (149). Controversial studies sug-
gested that Aurora-A abnormalities were positively correlated 
with aggressive tumor behavior invasion, and nodal metastasis, 
but some studies showed no correlation or an inverse correlation 
(150). The oncogenic effects of Aurora-A was attributed to its 
interaction with several important cellular proteins, including 
protein phosphatase 1, target protein for xklp2, HEF1, p53, 
CENP-A, Ajuba, and transforming acidic coiled-coil (141).
Even though the expression of the kinase from S to M phase 
and the localization of Aurora-A onto the centrosome and the 
spindle pole have been widely described, it becomes more and 
more evident that Aurora-A is present in all phases of the cell 
cycle and might fully participate in other functions that mitotic 
ones. Several recent studies have described non-mitotic func-
tions of Aurora-A in cellular calcium signaling, cilia resorption 
or cytoskeleton organization. The presence of diffuse Aurora-A 
staining in the cytosol, the Golgi and perinuclear region hinted 
that it had a possible role unrelated to mitosis (151).
Previous studies have shown a potential role of Aurora-A 
in metastasis and that Aurora-A ectopic expression induced a 
robust increase in cell migration through its effect on tubulin 
polymerization (147, 152). The mechanism by which the kinase 
is involved in the process of mobility, migration, and invasion is 
not completely defined but it has been suggested a role of RAS, 
AKT, RALa, and MAPKs (153). Aurora-A has been shown to 
be implicated in cell migration along with SRC and FAK and, 
unexpectedly, is regulated by a lipase, phospholipase D2 (PLD2). 
Phosphatidic acid is able to bind and activate Aurora-A causing 
rapid tubulin polymerization and leading to an enhanced cell 
migration (154). The action of Aurora-A on cell mobility has 
also been investigated through a group of proteins involved 
in the focal adhesion as NEDD9, SRC and FAK. The effect of 
Aurora-A on cell migration is augmented in the presence of SRC 
and, in return, Aurora-A also activates FAK. Cell migration is 
also physically mediated by actin cytoskeleton and is initiated 
by the protrusion of the cell membrane (155). Overexpression of 
Aurora-A regulates actin reorganization, leading to free barbed 
end formation. Cofilin has emerged as an essential player for 
the localized formation of the barbed ends, which act as sites for 
new local actin polymerization, thus determining the direction 
of cell protrusion and movement (156). A significant correlation 
between Aurora-A expression and cofilin dephosphorylation was 
described in the immunohistochemical analysis of clinical breast 
cancer specimens, supporting a novel signaling mechanism by 
which Aurora-A indirectly induced cofilin dephosphorylation 
and actin reorganization, thus promoting mammary cell 
movement and breast cancer metastasis (157). Most importantly, 
Aurora-A was demonstrated to enhance EMT and invasiveness via 
activation of MAPK signaling pathway. A novel oncogenic cross-
talk between Raf/MAPK and Aurora-A signaling pathways has 
been established in the development of EMT, stemness, and tumor 
progression in ERα breast cancer cells. The constitutive activation 
of MAPK signaling pathway during tumor growth leads to the 
stabilization and accumulation of Aurora-A which induces the 
EMT (158). Aurora-A inhibition by VX-680 induced a significant 
suppression of cell invasion ability, as well as reversed its EMT 
behavior by reducing membrane expression of epithelial markers 
E-cadherin and β-catenin in cervical CN2 cells (152, 159).
Recent studies have shown more diverse, non-mitotic functions 
of Aurora-A orchestrating remodeling of the microtubular 
cytoskeleton during neurite extension (160) but also regulating 
protrusion and resorption of cellular cilia participating in cellular 
calcium signaling (161, 162). Aurora was shown to localize 
at the basal body of the cilium and its activation was shown 
to participate to the ciliary resorption by promoting histone 
deacetylase-dependent tubulin depolymerization of the ciliary 
axoneme (161).
The serum growth factors were also shown to induce Aurora-A 
activation at the basal body of the cell cilium in non-cycling G0/G1 
cells causing Aurora-A and NEDD9-dependent cilia resorption 
(161). HEF1/Cas-L/NEDD9 is a component of focal adhesions that 
has a prominent role in inducing metastasis and that co-localizes 
with Aurora-A at the centrosome, thereby enhancing the effect of 
Aurora-A on the resorption of the cilium. After cilia resorption, 
Aurora-A ceases to be active (as judged by kinase activity) and 
will probably be reactivated for mitotic function as soon as the 
cell enters the cell cycle. By microinjecting active Aurora-A into 
cells, the cilium disappeared, leading to the conclusion that active 
Aurora-A is necessary and sufficient to induce cilium resorption 
(163). Loss of cilia associated with high level Aurora-A expression 
would indirectly impact the functionality of the cilia-dependent 
and cancer-relevant signaling cascades, such as those involving 
Hedgehog (164).
Pathological conditions of the kidney include renal cell 
carcinoma, in which elevated Aurora-A expression has (often) 
been reported (165) as well as its partner NEDD9 (72, 166, 167). 
Aurora-A pathway is induced through HIF (hypoxia-inducible 
factor-1) in ccRCC cells and has significant impact on two 
relevant features of VHL-defective cells: the suppression of 
primary cilia that in vivo can lead to premalignant cysts and the 
increased motility that can lead to metastasis (168). However, the 
underlying mechanism by which VHL loss increases Aurora-A 
levels has not been clearly elucidated, although it has been 
suggested that HIF-1α mediates increased Aurora-A expression 
in VHL-null cells. Dere et al suggested that Aurora-A expression 
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is driven by β-catenin transcription in the VHL null cells and that 
the level of Aurora-A was not modified by Hif1-α (169).
Clear cell renal cell carcinoma is also characterized by VHL 
inactivation and more recent data indicate that VHL interacts 
with primary cilia in renal epithelial cells. A hallmark of ccRCC 
is loss of the primary cilium. Loss of this key organelle in ccRCC 
is caused by loss of VHL and associated with increased Aurora-A 
and histone deacetylase 6 (HDAC6) activities, which drive disas-
sembly of the primary cilium. Aurora-A is typically described 
as solely localized to the centrosome or centrosomally derived 
ciliary basal body and otherwise hard to detect in non-cycling 
normal mammalian cells. Evidence that HEF1/Aurora-A/
HDAC6 signaling axis governs the resorption of cilia in addi-
tion to the previously defined roles for these proteins suggests a 
novel molecular mechanism to explain some cancer-associated 
ciliary loss. The focal adhesion protein HEF1 initially interacts 
with Aurora-A in G2 prior to the kinase activation. As the cell 
progresses throughout the cell cycle, focal adhesion disassembly 
releases a pool of HEF1, which promotes Aurora-A activation. 
Overexpression of HEF1 and Aurora-A promotes cytokinetic 
failure, and contributes to genomic instability. The protein 
association may interfere with a normal cellular interconversion 
between cilia and centrosome and contributes to cell cycle by 
staging critical signaling complexes that govern emergence from 
quiescence to S phase, and initiation of M phase.
Interestingly, formation of renal cysts is very strongly linked 
to defects in planar cell polarity control (170, 171). Aurora-A has 
also been found to directly phosphorylate Par-6, which together 
with atypical PKC and Par-3 regulate asymmetric cell division and 
cell polarity (172) and the changes in Ca2+ signaling induced by 
autosomal-dominant PKD (ADPKD)-associated mutations in the 
PKD1 and PKD2 genes (173–175). Low concentrations of drugs 
that inhibit Aurora-A activity raise basal intracellular Ca2+ levels 
in renal cells and PC2-dependent Ca2+ release. It has been also 
demonstrated that Aurora-A directly binds and phosphorylates 
PC2, and consequently may provide a mechanism by which 
Aurora-A inhibition limits PC2 Ca2+ channel activity. Moreover, 
the release of Ca2+ from the ER to the cytoplasm transiently 
activated Aurora-A, based on induced direct Ca2+-calmodulin 
(CaM) binding to Aurora-A. The non-mitotic activities of 
Aurora-A likely contribute to deregulation of growth in tumor 
cells overexpressing Aurora-A (Figure 2).
CONCLUSiON
Clear cell renal cell carcinoma is the predominant type of 
kidney cancer. ccRCC develops in the renal proximal tube and 
is linked to biallelic inactivation of the VHL tumor suppressor 
gene. Mitotic kinases defects mostly lead to aneuploid tumors 
and the sustained overexpression and activity of various mitotic 
kinases, including Aurora-A, Polo-like (Plk1), CK2, DCLK in 
diverse human tumors strongly indicate that these entities are 
intimately involved in the development of errors in chromosome 
segregation. Nevertheless, the non-mitotic functions of these 
kinases involved in the process of ciliogenesis, hypoxia, the EMT 
as well as the cell polarity likely play an important role in the 
process of tumorigenesis in kidney cancer as they also lead to 
genetic instability.
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